James G Kublin

List of Publications by Year
in descending order

57 papers	3,977 citations	236833 25 h-index	143943 57 g-index
60 all docs	60 docs citations	60 times ranked	4842 citing authors

#	Article	IF	Citations
1	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 2022, 375, 43-50.	6.0	788
2	Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. New England Journal of Medicine, 2013, 369, 2083-2092.	13.9	518
3	Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infectious Diseases, The, 2011, 11, 507-515.	4.6	330
4	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. New England Journal of Medicine, 2021, 384, 1003-1014.	13.9	270
5	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 2021, , eab3435.	6.0	145
6	Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120â€“MF59 in Adults. New England Journal of Medicine, 2021, 384, 1089-1100.	13.9	144
7	Tuberculosis Vaccines and Prevention of Infection. Microbiology and Molecular Biology Reviews, 2014, 78, 650-671.	2.9	133
8	Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. Journal of Clinical Investigation, 2012, 122, 359-367.	3.9	127
9	Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infectious Diseases, The, 2014, 14, 388-396.	4.6	108
10	Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects. Science Translational Medicine, 2017, 9, .	5.8	91
11	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV,the, 2018, 5, e366-e378.	2.1	86
12	Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathogens, 2016, 12, e1005742.	2.1	81
13	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. Statistical Communications in Infectious Diseases, 2017, 9, .	0.2	62
14	Increasing Black, Indigenous and People of Color participation in clinical trials through community engagement and recruitment goal establishment. PLoS ONE, 2021, 16, e0258858.	1.1	62
15	HIV-1 Vaccines and Adaptive Trial Designs. Science Translational Medicine, 2011, 3, 79ps13.	5.8	60
16	Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. Lancet HIV,the, 2020, 7, e688-e698.	2.1	58
17	A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa. EClinicalMedicine, 2020, 21, 100313.	3.2	52
18	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Science Translational Medicine, 2019, 11, .	5.8	46

#	Article	IF	Citations
19	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. Lancet HIV,the, 2019, 6, e737-e749.	2.1	43
20	Beyond Blood Smears: Qualification of Plasmodium 18S rRNA as a Biomarker for Controlled Human Malaria Infections. American Journal of Tropical Medicine and Hygiene, 2019, 100, 1466-1476.	0.6	41
21	Lessons Learned from HIV Vaccine Clinical Efficacy Trials. Current HIV Research, 2014, 11, 441-449.	0.2	38
22	Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials. Vaccine, 2015, 33, 2347-2353.	1.7	34
23	PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection. PLoS Pathogens, 2021, 17, e1009594.	2.1	34
24	Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. PLoS ONE, 2015, 10, e0137666.	1.1	30
25	Enhancing Diversity in the Public Health Research Workforce: The Research and Mentorship Program for Future HIV Vaccine Scientists. American Journal of Public Health, 2015, 105, 823-830.	1.5	28
26	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: AÂrandomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Medicine, 2020, 17, e1003038.	3.9	27
27	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. PLoS ONE, 2017, 12, e0185959.	1.1	27
28	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. Open Forum Infectious Diseases, 2022, 9, ofac124.	0.4	25
29	A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens. Statistical Communications in Infectious Diseases, 2011, 3, .	0.2	23
30	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. PLoS ONE, 2015, 10, e0136626.	1.1	23
31	Safety and Comparability of Controlled Human Plasmodium falciparum Infection by Mosquito Bite in Malaria-NaÃ¯ve Subjects at a New Facility for Sporozoite Challenge. PLoS ONE, 2014, 9, e109654.	1.1	21
32	Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination. PLoS ONE, 2019, 14, e0225622.	1.1	20
33	Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. PLoS Medicine, 2021, 18, e1003868.	3.9	20
34	In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Nonvaccine Prevention Modalities. AIDS Research and Human Retroviruses, 2013, 29, 1513-1523.	0.5	19
35	Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. PLoS Pathogens, 2021, 17, e1009363.	2.1	19
36	Antigenic competition in CD4 ⁺ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. Science Translational Medicine, 2019, 11, .	5.8	18

#	Article	IF	Citations
37	Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study. Scientific Reports, 2018, 8, 6066.	1.6	17
38	HIV Vaccine Trials Network: activities and achievements of the first decade and beyond. Clinical Investigation, 2012, 2, 245-254.	0.0	16
39	Mobile Phone Questionnaires for Sexual Risk Data Collection Among Young Women in Soweto, South Africa. AIDS and Behavior, 2018, 22, 2312-2321.	1.4	16
40	Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. PLoS ONE, 2016, 11, e0161753.	1.1	16
41	Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. Clinical Infectious Diseases, 2020, 72, 50-60.	2.9	15
42	Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models. EBioMedicine, 2015, 2, 2062-2069.	2.7	14
43	Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. Current Opinion in Virology, 2016, 17, 57-65.	2.6	14
44	Reference and point-of-care testing for G6PD deficiency: Blood disorder interference, contrived specimens, and fingerstick equivalence and precision. PLoS ONE, 2021, 16, e0257560.	1.1	12
45	The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States. Vaccines, 2017, 5, 13.	2.1	11
46	Analysis of the HIV Vaccine Trials Network 702 Phase 2bâ€“3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. Journal of Infectious Diseases, 2022, 226, 246-257.	1.9	11
47	Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults. Clinical Infectious Diseases, 2020, 71, 1481-1490.	2.9	9
48	Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses. PLoS ONE, 2014, 9, e103446.	1.1	9
49	Utilizing gnotobiotic models to inform the role of the microbiome in vaccine response heterogeneity. Current Opinion in HIV and AIDS, 2018, 13, 1-8.	1.5	8
50	A mixed methods investigation of implementation barriers and facilitators to a daily mobile phone sexual risk assessment for young women in Soweto, South Africa. PLoS ONE, 2020, 15, e0231086.	1.1	8
51	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. PLoS Medicine, 2020, 17, e1003117.	3.9	8
52	Lower Viral Loads and Slower CD4⁺T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02. Journal of Infectious Diseases, 2016, 214, 379-389.	1.9	6
53	Competing biomedical HIV prevention strategies: potential costâ€effectiveness of HIV vaccines and PrEP in Seattle, WA. Journal of the International AIDS Society, 2019, 22, e25373.	1.2	6
54	Daily Vaginal Swabs and Mobile Phone Sex Report for Assessing HIV Virion Exposure Prospectively Among a Cohort of Young Sexually Active Women in South Africa (HVTN 915). Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, e39-e48.	0.9	5

#	Article	IF	Citations
55	A New Model for Catalyzing Translational Science: The Early Stage Investigator Mentored Research Scholar Program in HIV Vaccines. Clinical and Translational Science, 2015, 8, 166-168.	1.5	4
56	Use of placebos in Phase 1 preventive HIV vaccine clinical trials. Vaccine, 2015, 33, 749-752.	1.7	2
57	Vaginal practices among women at risk for HIV acquisition in Soweto, South Africa. Southern African Journal of HIV Medicine, 2019, 20, 866.	0.3	2